Previous 10 | Next 10 |
PARSIPPANY, NJ, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, today announced that on February 16, 2020 it had received notification from the Listing Qualif...
PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to shareholders: Dear Shareholders, As the newly appointed President and CEO of ...
Interpace Biosciences (IDXG) names Tom Freeburg, accounting chief to CFO post. Mr. Freeburg succeeds Fred Knechtel effective February 1, 2021.Mr. Freeburg has been with Interpace since 2017 and brings over 20 years of financial and executive experience to his new...
PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has appointed Tom Freeburg, Chief Accounting Officer, as Interpace’s Chief ...
Interpace Biosciences ([[IDXG]] +5.0%) announces that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody platform, Das-1, used in the risk assessment of pancreatic cysts.In a recent, national...
Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody platform, Das-1, us...
In-network status for ThyGeNEXT ® and ThyraMIR ® with State’s Largest Payer PARSIPPANY, NJ, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the Company’s Diagnostics group has entered in to a contract ...
PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast after the close of market on Thursday, January 21, 2021 at 4:30 p.m. ET. Purpose: To ...
Interpace Biosciences (IDXG): FQ3 GAAP EPS of -$1.53 misses by $0.33.Revenue of $8.25M (+6.7% Y/Y) beats by $0.63M.Shares -3.49% PM.Press Release For further details see: Interpace Biosciences EPS misses by $0.33, beats on revenue
Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior Year Estimates Fourth Quarter Net Revenue range of $9.0 million - $10.0 million Realized Reimbursement on Higher ThyGeNEXT Pricing in Ja...
News, Short Squeeze, Breakout and More Instantly...
Interpace Biosciences Inc. Company Name:
IDXG Stock Symbol:
NASDAQ Market:
Interpace Biosciences Inc. Website:
PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics ® , a subsidiary of Interpace Biosciences ® (OTCQX: IDXG), is proud to announce that new data demonstrating the application of advanced sequencing technologies in pancreatic cancer was published as an e-ab...
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update. First quarter Net ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...